|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | TYPE 2 DIABETES: EVALUATING THE EFFECTS OF CLARAMINE ON INSULIN- MEDIATED GLUCOSE REGULATION IN HEPATOMA (HEPG2) CELL LINE. |
| Authors Name: | DR. LAMIDI, TAJUDEEN BABATUNDE , KILEDU, ISREAL AHMADU |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_205279
|
| Published Paper Id: | IJNRD2311078 |
| Published In: | Volume 8 Issue 11, November-2023 |
| DOI: | |
| Abstract: | ABSTRACT Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. The most common is type 2 diabetes, usually in adults, which occurs when the body becomes resistant to insulin or doesn't make enough insulin. Protein tyrosine phosphatises (PTPs) are critical antagonist of insulin receptor (IR) signalling. Their inhibition with pharmacological inhibitory agents can play the role of insulin thus facilitating the uptake of glucose and the inhibition of lipolysis. Elevated PTPIB activity underlies insulin resistance in type 2 diabetes. Several experiments have shown that PTPIB is implicated in glucose regulation obesity and type-2 diabetes. Claramine is a novel synthetic chemical agent which possess selective inhibitory activity against PTPIB. This research was aimed at unveiling the effects of claramine on insulin-mediated glucose regulation in Hepatoma (HepG2) cell lines. Research materials including Hep G2 cell line, T-75 flasks, Eppendorf tubes, 96-well plates, Bradford reagent test kit, cell culture media (Dulbecco's Modified Eagle Medium) (DMEM) and all reagents for buffer preparation was purchased. First experiment was conducted to test the viability of the HepG 2 cell lines using standard procedure. Second round of experiment was conducted to culture the HepG 2 cells at 37OC. The cells were divided into 6 wells plates and allowed to adhere for 24 hours. After adherence, the cells were treated with high glucose and different concentrations of insulin and claramine. The determination of glucose utilisation by the cells was done with multiscan-FC spectrophotometer at 540nm and the amount of glucose utilised by the cell was calculated and use for protein normalisation. Combination of 50nm of insulin with various concentrations of claramine showed trend in the uptake of glucose by Hep2 cells with highest uptake at 2.0um of claramine. However, with 100nm insulin there was relative little and irregular variation in glucose uptake by HepG 2 cells with different concentrations of claramine. Also, glucose utilisation with respect to joint variation of insulin and claramine concentrations showed increase uptake at 50nm insulin and 1um claramine. Hepatoma cell lines can be used to investigate the glucose uptake and glucose metabolism in hepatocyte. claramine is a first class highly selective inhibitor of protein tyrosine phosphtase IB (PTPIB). It is therefore eminent that inhibitors of PTPIB plays important role as efficient therapeutic target for type-II diabetes and obesity by increasing insulin and leptin sensitivity. |
| Keywords: | Keywords: Diabetes, Insulin, PTPs, Claramine, Hepatoma cell line, Metabolic disease |
| Cite Article: | "TYPE 2 DIABETES: EVALUATING THE EFFECTS OF CLARAMINE ON INSULIN- MEDIATED GLUCOSE REGULATION IN HEPATOMA (HEPG2) CELL LINE.", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 11, page no.a710-a719, November-2023, Available :http://www.ijnrd.org/papers/IJNRD2311078.pdf |
| Downloads: | 000118768 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2311078 Registration ID: 205279 Published In: Volume 8 Issue 11, November-2023 DOI (Digital Object Identifier): Page No: a710-a719 Country: BALI, TARABA , Nigeria Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2311078 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2311078 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn